Author

Mario Maldonado

Observed names: M. Maldonado, MARIO MALDONADO

Observed institutions: Universidade Federal do Rio de Janeiro, Universitat Autònoma de Barcelona, Novartis (Switzerland), Agricultural Research Service, United States Department of Agriculture, The University of Texas MD Anderson Cancer Center, University of Massachusetts Chan Medical School, Baylor College of Medicine, Ben Taub Hospital, Hospital de Sant Pau, MSD (UK) Limited (United Kingdom), Antwerp University Hospital, Centre for Biomedical Network Research on Rare Diseases, Children's Nutrition Research Center at Baylor College of Medicine

OpenAlex ID: A5113588010

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

2000 · Peter J. Trainer, William M. Drake, et al. · New England Journal of Medicine · 876

PDF

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

2012 · Annamaria Colao, Stephan Petersenn, et al. · New England Journal of Medicine · 628

PDF

Ketosis-Prone Diabetes: Dissection of a Heterogeneous Syndrome Using an Immunogenetic and β-Cell Functional Classification, Prospective Analysis, and Clinical Outcomes

2003 · Mario Maldonado, Christiane S. Hampe, et al. · The Journal of Clinical Endocrinology & Metabolism · 236

Syndromes of Ketosis-Prone Diabetes Mellitus

2008 · Ashok Balasubramanyam, Ramaswami Nalini, et al. · Endocrine Reviews · 200

PDF

LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study

2013 · Xavier Bertagna, Rosario Pivonello, et al. · The Journal of Clinical Endocrinology & Metabolism · 188

PDF

High variability in baseline urinary free cortisol values in patients with Cushing's disease

2013 · S. Petersenn, J. Newell‐Price, et al. · Clinical Endocrinology · 147

PDF

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

2014 · Rosario Pivonello, Stephan Petersenn, et al. · Clinical Endocrinology · 117

Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of “A-β+” ketosis-prone diabetes based on long-term β-cell function, human leukocyte antigen class II alleles, and sex predilection

2010 · Ramaswami Nalini, Kerem Ozer, et al. · Metabolism · 60

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

2013 · M. Boscaro, J. Bertherat, et al. · Pituitary · 50

PDF

Psychometric Evaluation of the Cushing’s Quality-of-Life Questionnaire

2013 · Lauren M. Nelson, Anna Forsythe, et al. · Patient · 39

Regression of acanthosis nigricans correlates with disappearance of anti–insulin receptor autoantibodies and achievement of euglycemia in type B insulin resistance syndrome

2007 · Gilbert G. Fareau, Mario Maldonado, et al. · Metabolism · 39

Fenofibrate Is Effective in Treating Hypertriglyceridemia Associated with HIV Lipodystrophy

2004 · Archana Rao, Susana D’Amico, et al. · The American Journal of the Medical Sciences · 37

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease

2014 · Susan M Webb, John E Ware, et al. · European Journal of Endocrinology · 29

HLA Class II Alleles Specify Phenotypes of Ketosis-Prone Diabetes

2008 · Ramaswami Nalini, Lakshmi K. Gaur, et al. · Diabetes Care · 29

PDF

An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers

2012 · Magdy Shenouda, Mario Maldonado, et al. · American Journal of Therapeutics · 28

Presence of the metabolic syndrome distinguishes patients with ketosis-prone diabetes who have a Type 2 diabetic phenotype

2005 · Max E. Otiniano, Ashok Balasubramanyam, et al. · Journal of Diabetes and its Complications · 26

Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome

2006 · Susana D’Amico, Jianjian Shi, et al. · American Journal of Clinical Nutrition · 21

PDF

Predictors of glycaemic control in indigent patients presenting with diabetic ketoacidosis

2005 · M. Maldonado, S. D'Amico, et al. · Diabetes Obesity and Metabolism · 19

Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study

2012 · Stephan Petersenn, Ke Hu, et al. · Clinical Therapeutics · 17

Accuracy and Predictive Value of Classification Schemes for Ketosis-Prone Diabetes

2007 · Ashok Balasubramanyam, Mario Maldonado · Diabetes Care · 10

PDF

Diabetic ketoacidosis associated with Metabolife: a report of two cases

2002 · C. C. Case, M. Maldonado · Diabetes Obesity and Metabolism · 7

Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome

2025 · Antoine Tabarin, Jérôme Bertherat, et al. · The Journal of Clinical Endocrinology & Metabolism · 5

Changes in Metabolic Profile Among Antiretroviral-Naive Patients Initiating Protease Inhibitor Versus Non–Protease Inhibitor Containing HAART Regimens

2003 · Fehmida Visnegarwala, Jorge Darcourt, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 5

Effect of Ertugliflozin on Initial eGFR Decline and Chronic Slope: Analyses from the VERTIS CV Trial

2020 · David Cherney, Bernard Charbonnel, et al. · Journal of the American Society of Nephrology · 4

Pasireotide (SOM230) Demonstrates Efficacy in Patients with Cushing Disease: Results from a Large, Randomized-Dose, Double-Blind, Phase III Study

2011 · Annamaria Colao, Stephan Petersenn, et al. · The Endocrine Society eBooks · 4

Works count: 35

Citation count: 2,831

H-index: 18

I10-index: 20